# Freenome

its SimpleScreen colorectal-cancer blood test met all primary and secondary endpoints (85% sensitivity for CRC, 22% for advanced precancerous lesions), alongside separate multiomic lung-cancer screening data.

Source: https://en.bioecon.ru/companies/freenome/
Updated: 2026-07-20

- Country: United States

## Technologies

- [Multi-cancer early detection (MCED)](https://en.bioecon.ru/technology/multi-cancer-early-detection/)